Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, has announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of US$10 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be US$150 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on November 16, 2026, subject to customary closing conditions.

Latham & Watkins LLP advised the underwriters in the transaction with a corporate team led by Orange County partner Drew Capurro, with associates Greg Van Buiten, Caitlin Nguyen, and Brock Meyer. Advice was also provided on regulatory matters by Bay Area partners Heather Deixler and Betty Pang and Washington, D.C. counsel Chad Jennings, with associate Kris Kenn; on intellectual property matters by San Diego counsel Rob Yeh, with associate Andrew Wang; and on tax matters by Bay Area partner Grace Lee, with assistance from Francis Shih.